Westhampton Capital LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Westhampton Capital LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,063 shares of the biopharmaceutical company’s stock after acquiring an additional 170 shares during the period. Westhampton Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $757,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Adirondack Trust Co. raised its holdings in Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. increased its position in shares of Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares during the last quarter. Trust Co. of Vermont raised its stake in shares of Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 12 shares in the last quarter. Nvwm LLC lifted its position in shares of Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 14 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 3.6% in the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $687.27 on Thursday. The firm’s 50 day simple moving average is $724.48 and its 200-day simple moving average is $930.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $75.52 billion, a P/E ratio of 17.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10.

Analyst Upgrades and Downgrades

A number of research analysts have commented on REGN shares. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.